EXAS

NEUTRALM&A

Exact Sciences Corporation

2026-03-03

Price

$103.37

+0.02%

Score7.5Priority

Signals5/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume1.2xvs 20d avg

Analysis

Exact Sciences is no longer trading on standalone fundamentals; it is now a Merger Arbitrage 'Special Situation' tethered to Abbott Laboratories' (ABT) pending acquisition at $105/share. The current price of $103.37 reflects a ~1.5% deal spread, which is holding firm despite the 'Iran War' risk-off macro backdrop that is crushing broader indices. The 'Steady Climb' and 'Alpha Male' signals are not indicating organic growth, but rather the mechanical closing of the arbitrage gap following the February 20, 2026 shareholder approval. In this environment, EXAS acts as a defensive cash-proxy, decoupled from the plunging Dow.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONSMA BOUNCE

Key Takeaways

**Thesis:** Merger Arbitrage. The stock is pinned to the $105.00 acquisition price. The current 1.5% spread represents the remaining regulatory/time-value risk.
**Execution:** The 'Risk Off' macro regime creates a unique opportunity; if market panic widens the spread (drops price below $102.50), it is a high-probability 'buy the discount' trade.
**Risk:** Regulatory Intervention (FTC). While shareholder approval is secured, any antitrust noise could blow out the spread. Watch for 'Second Request' headlines.

← Back to 2026-03-03 View Full EXAS History →Yahoo Finance &nearr;